PT  - JOURNAL ARTICLE
AU  - Xuan Liu
AU  - Jianyun Wen
AU  - Yiqi Xu
AU  - Yongsheng Ruan
AU  - Tiantian Yi
AU  - Jung-Chien Chen
AU  - Xuedong Wu
TI  - Increased risk of arterial thromboembolic events in transfusion-naïve thalassemia: a nationwide population-based study
AID  - 10.1136/jim-2018-000790
DP  - 2019 Jun 01
TA  - Journal of Investigative Medicine
PG  - 826--832
VI  - 67
IP  - 5
4099  - http://hw-f5-jim.highwire.org/content/67/5/826.short
4100  - http://hw-f5-jim.highwire.org/content/67/5/826.full
SO  - J Investig Med2019 Jun 01; 67
AB  - Transfusion-naïve thalassemia minor/trait is often associated with decreased risk of coronary artery diseases. The present study aimed to evaluate the effect of transfusion-naïve thalassemia on the incidence of arterial thromboembolic events using the National Health Insurance Research Database, Taiwan (2001–2010). Data from patients with transfusion-naïve thalassemia (n=2356) frequency matched with non-thalassemia subjects (n=9424) according to sex, age, and index year at a ratio of 1:4 were included. The risk of arterial thromboembolic events, cerebrovascular ischemic events, arterial embolism/thrombosis, peripheral embolism, myocardial infarction, myocardial ischemia, and angina pectoris in transfusion-naïve thalassemia were analyzed using Cox proportional hazard regression models. The transfusion-naïve thalassemia group had significantly higher risk of arterial thromboembolic events (aHR=1.28, 95% CI 1.07 to 1.52) and myocardial ischemia (aHR=1.41, 95% CI 1.13 to 1.76) as compared with the non-thalassemia group. In addition, they also had a significantly higher cumulative incidence of arterial thromboembolic event and myocardial ischemia. Interestingly, a higher risk of arterial thromboembolic events (aHR=1.58, 95% CI 1.22 to 2.04) and myocardial ischemia (aHR=1.73, 95% CI 1.25 to 2.41) was observed in men with thalassemia as compared with those without. Furthermore, patients with comorbidities had an increased risk of arterial thromboembolic events than did those without comorbidities. The effect of thalassemia on arterial thromboembolic events may be mainly attributed to the influence of thalassemia on myocardial ischemia, as no significant differences were observed in other outcomes evaluated in the present study. In conclusion, the present study confirms the increased risk of arterial thromboembolic events, mainly attributed to the dramatic increase in myocardial ischemia, inminor patients with transfusion-naïve thalassemia.